FDA Approves Updated Labeling for Menopausal Hormone Therapy Products to Increase Availability and Improve Care

The U.S. Food and Drug Administration (FDA), through the Department of Health and Human Services, has approved updated labeling for three additional menopausal hormone therapy (MHT) products from two applicants. This action is part of ongoing efforts to expedite appropriate manufacturing changes, aiming to increase the capacity and availability of MHT for Americans.